Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says

Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of neuroendocrine tumor.

Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

ITM’s radiotherapeutic beats out standard-of-care in Phase III trial - Pharmaceutical Technology

the company announced that its Phase III trial examining its gastroenteropancreatic tumour treatment, ITM-11, met its primary endpoint.

177Lu-edotreotide Improves PFS in Grade 1/2 GEP-NETs in Phase 3 COMPETE Trial

177Lu-edotreotide prolonged PFS vs everolimus in patients with inoperable, progressive, grade 1 or 2 gastroenteropancreatic neuroendocrine tumors.

ITM aims to compete with Novartis after Phase 3 radiopharma win

ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said Tuesday. Treatment with ITM-11 prolonged progression ...

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Pipelinereview

Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimus ITM plans to submit the COMPETE data for presentation at a future medical conference, with potential US regulatory submission anticipated in 2025 ITM continues to advance a broad clinical pipeline, with multiple assets being investigated across seven differe…